Study of Bronchiectasis and Associated Cardiovascular Comorbidities
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Echocardiography.
- Who it may be relevant to
- Registry conditions: Bronchiectasis. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effect of Cardiovascular Comorbidities on Disease Severity and Quality of Life in Patients With Acute Exacerbation of Non-cystic Fibrosis Bronchiectasis
Overview
Effect of cardiovascular comorbidities on disease severity and quality of life in Patients with acute exacerbation of non-cystic fibrosis bronchiectasis
Detailed description
The study will include patients with bronchiectasis, and in an attempt to correlate the effect and burden of cardiovascular comorbidities in those patients, we will study the quality of life in those patients in comparison to the control group ( patients with bronchiectasis and without any other comorbidities) using SF-36 quality of life questionnaire. We will also study the inflammatory markers in both groups using D-dimer, BNP, and CRP and correlate them with the frequency of hospital admission, the severity of symptoms, and the general health state.
Interventions
- Device Echocardiography
echocardiographic study of both groups
Primary outcome measures
- assessment of BNP (Brain natriuretic peptide) pg/ml levels in patients with bronchiectasis and cardiovascular comorbidities. [Time frame: March 2023 to September 2023]
- Assessment of Quality of life in patients and control groups using The Short Form (36) Health Survey (SF-36) [Time frame: March 2023 to September 2023]
Secondary outcome measures (1)
- Hospitalization frequency in patient group compared to control group. [Time frame: March 2023 to September 2023]
Eligibility criteria
Inclusion criteria
- Any Patients with Bronchiectasis had no comorbidities other than cardiovascular comorbidities during the study period.
Exclusion criteria
- Any Patients who refuse to participate in the study.
- Any other comorbidity or end-organ failure may affect the study's result.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-control
Study locations
Egypt · 1 center
- Assiut unviresty - Faculty of Medicine — Asyut
Identifiers
NCT: NCT05783869 · 23455668